denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Description:
Discoveries during the last 20 years have transformed our understanding of thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies, and ongoing investigations should further improve the prognosis for patients with this disease.
Dr. J. Evan Sadler will review recent advances in the diagnosis and pathophysiology of TTP, which have sharpened the clinical distinctions between TTP and other disorders associated with thrombotic microangiopathy. Precise, rapid diagnosis should facilitate the administration of specific therapy and further improve prognosis.
Dr. Paul Coppo will summarize the state of the art in TTP therapy, with a particular focus on the use of immunosuppressive therapy at initial diagnosis, for refractory disease, and prophylactically to prevent relapse. He also will review the status of novel agents that target the covalent structure of VWF or inhibit VWF-platelet interactions.
Dr. James George will address the evaluation and management issues of thrombotic microangiopathies that occur in association with pregnancy. He will review data that provide a clinical approach to the pregnant woman who may have preeclampsia/HELLP syndrome, TTP, or complement-mediated thrombotic microangiopathy.